Company profile for Amzell B.V

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Amzell BV is a specialist, virtual development pharmaceutical company which takes candidate or re purposed drugs and devices either through to proof of concept, or through to registration for sale to commercial healthcare companies. The company, which is based in Hoofddorp in the Netherlands, was founded in 2016 and is part of the Frederik Paulsen business interests which consists of a number of healthcare companies includi...
Amzell BV is a specialist, virtual development pharmaceutical company which takes candidate or re purposed drugs and devices either through to proof of concept, or through to registration for sale to commercial healthcare companies. The company, which is based in Hoofddorp in the Netherlands, was founded in 2016 and is part of the Frederik Paulsen business interests which consists of a number of healthcare companies including Ferring Pharmaceuticals.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Siriusdreef 41 2132WT Hoofddorp, Netherlands
Telephone
Telephone
+31 23 55 60 465
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20211202005641/en/Amzell-B.V.-and-Amring-Pharmaceuticals-Inc.-Attending-2021-American-Epilepsy-Society-Meeting-in-Chicago

BUSINESSWIRE
02 Dec 2021

https://www.businesswire.com/news/home/20211119005740/en

BUSINESSWIRE
19 Nov 2021

https://www.businesswire.com/news/home/20211119005740/en/Amzell-B.V.-in-Collaboration-With-Amring-Pharmaceuticals-Inc.-Announce-Their-Lead-Product-Has-Entered-Phase-III-Clinical-Trial-in-the-U.S.-for-Treatment-of-Infantile-Epileptic-Disease

BUSINESSWIRE
19 Nov 2021

http://www.pharmabiz.com/NewsDetails.aspx?aid=133783&sid=2

PHARMABIZ
27 Nov 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty